New Hope for APL Patients: Drug Repurposed

Acute Promyelocytic Leukemia (APL), once highly curable, presents challenges when standard arsenic trioxide therapy fails in 8-10% of patients. In these cases, cancer cells adapt by altering their survival strategies, deriving energy from mitochondria and increasing protective BCL2 protein. This resistance limits treatment options significantly.

Researchers have identified Venetoclax, an approved cancer drug, as a potential solution. This drug works by cutting off the cancer cells' energy supply and reactivating their natural destruction processes. Studies in mouse models demonstrated Venetoclax's effectiveness at low doses, significantly reducing tumor burden and improving survival.

The combination of Venetoclax with arsenic trioxide yielded even stronger results, with greater tumor shrinkage and increased survival rates. As Venetoclax is already in clinical use for other blood cancers, this discovery paves the way for designing new treatment strategies for relapsed APL patients, offering fresh hope especially in India.